Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
Taltz® (ixekizumab): Air bubbles
Air bubbles in the pre-filled pen and the pre-filled syringe are normal. They will not harm the user or affect the dose.
It is normal to sometimes see an air bubble / air bubbles in the Taltz device. Taltz is injected under the skin (subcutaneous injection). Air bubbles are not a problem in this type of injection. They will not harm the user or affect the dose.1
The air bubble is a normal part of the syringe manufacturing process for Taltz devices.2
The user should not try to remove or expel the air bubble in the device. Removal of the air bubble before injecting is not necessary and not recommended. Doing so can affect the dose.2
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: November 05, 2020